Company intelligence / Profile preview
TaiRx, Inc.
Taipei, Taipei City, Taiwantrx.com.tw ↗
- Ownership
- Public · 6580
- Development stage
- Phase 2
01
Overview
TaiRx’s lead program CVM‑1118 has advanced to Phase II trials for multiple solid tumor indications including hepatocellular carcinoma and neuroendocrine tumors. Zelnite® has been approved by the Taiwan FDA as an injectable selenium supplement. The company also develops preclinical programs in antibody-drug conjugates and oral chemotherapeutics.
- Therapeutic areas
- GastroenterologyOncologyInfectious Diseases
- Modalities
- Small moleculesAntibody-drug conjugatesOral drug formulationsInnovative antibody drugsDiagnostic devicesInjectionOral supplement
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
In-license agreements with Northwestern University & Ann & Robert H. Lurie Children’s Hospital of Chicago for global development rights using Nodal as a new targetSeeking additional partners/licensing opportunities
04
Financials
- Market cap
- $38M
- Total revenue
- $850.8K
- Enterprise value
- $29.6M
Beyond the preview
Go deeper on TaiRx, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TaiRx, Inc..